02:09 AM EST, 11/03/2026 (MT Newswires) -- Lytix Biopharma's (LYTIX.OL) ruxotemitide in combination with pembrolizumab achieved the primary endpoint of pathological complete response during a phase 2 study. Results from the NeoLipa study achieved a pathological complete response rate of at least 40%, meeting its prespecified success criterion, the clinical-stage immuno-oncology company said Tuesday. No new safety signals were identified so far. Lytix plans to conduct the randomized final phase of the study to compare ruxotemitide plus pembrolizumab with pembrolizumab alone, with event-free survival as the primary endpoint.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.